Pharmaceutical Executive, Apr 1, 2011 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Apr 1, 2011
Features
White Coats & Suit Jackets: A Coming-of-Age Story
The parnership between academia and industry is evolving. Will it keep innovation at a premium?
The Big Business of Boosting Performance
By William Looney
Dutch-based DSM N.V. is seeking innovatinve ways to partner through bolstering manufacturing
How US Health Reform Is Hitting Canada
By William Looney
Canada's Russell Williams, of Rx&D, talks about the impact of US health reform on his role as chief spokesman for the country's R&D industry
HBA Woman of the Year: Freda Lewis-Hall
By Jennifer Ringler
The determination of Pfizer's Freda Lewis-Hall has enabled her to find a ray of hope in every situation she's encountered
Special Section
Special Section: Pharma Meetings
Merck mounts pharma's first virtual symposium and interactive poster session
From the Editor
Platforms for Peerless Performance
By William Looney
A true performance culture has to focus on the mundane as much as the sublime
Columns
Dalli's Formula Fails the Efficacy Test
By Reflector
EU leadership on pharma policy leaves many wondering of the right man is at the helm
Winning Beyond the Molecule
By Stan Bernard, MD
It can take both a clinical and non-clinical approach to win the differentiation competition
The Death of a Sales Model?
These days, learning to strategically do more with less can keep your sales force performing at a high level
Bridging the HCP-Patient Gap
Pfizer's Sarah Krug describes what's necessary to bridge the gap between the patient revolution and healthcare provider in the 21st century
Off-Label But On Point?
Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help
Restoring Public Trust in Pharma
GSK's Deirdre Connelly puts the focus on four steps to cement a new compliance culture
Pharm Exec Wins a Neal Award!
By Jeff Schindler
William Looney, Editor-in-Chief, last month took home the award for "Best Commentary"
Revisiting Reform
By Jill Wechsler
Courts, Congress review policies and programs shaping drug costs and access

ADVERTISEMENT

Click here